LONDON, Dec 10 () - Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by ​30% compared with standard endocrine therapy, in what it said marked ‌the first big advance in hormonal treatment for the disease in over 20 years. The Swiss ‌drugmaker said detailed results from the phase III lidERA trial showed at three years, 92.

For tech lovers, cell phones are specialized gadgets as well as useful assets that offer a bunch of highlights and capacities.

Scientists may have "heard" the first tantalizing evidence of primordial black holes formed directly from overly dense pockets of matter just after the Big Bang.